Passage BIO, Inc.·4

Mar 2, 5:42 PM ET

SQUINTO STEPHEN P 4

4 · Passage BIO, Inc. · Filed Mar 2, 2020

Insider Transaction Report

Form 4
Period: 2020-02-27
SQUINTO STEPHEN P
DirectorHead of Research and Dev
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    2020-02-27+185,776185,776 total
    Exercise: $18.00Exp: 2030-02-27Common Stock (185,776 underlying)
  • Award

    Director Stock Option (Right to Buy)

    2020-02-27+33,83633,836 total
    Exercise: $18.00Exp: 2030-02-27Common Stock (33,836 underlying)
Footnotes (2)
  • [F1]The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date.
  • [F2]The option vest as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION